{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:25:18Z","timestamp":1789673118639,"version":"4.0.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.eprac.2025.09.205","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:05:03Z","timestamp":1759341903000},"page":"258-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Reliable Monitoring of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Using Imaging: A Systematic Literature Review and Meta-Analysis on Measurement Repeatability"],"prefix":"10.1016","volume":"32","author":[{"given":"Michael","family":"Ndaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant K.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Swensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niharika","family":"Samala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Ajaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid S.","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Akisik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.eprac.2025.09.205_bib1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.205_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.205_bib3","article-title":"Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025","volume":"10","author":"Lin","year":"2020","journal-title":"Sci Rep"},{"issue":"13","key":"10.1016\/j.eprac.2025.09.205_bib4","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186425","article-title":"Therapeutic horizons in metabolic dysfunction\u2013associated steatohepatitis","volume":"135","author":"Newsome","year":"2025","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.205_bib5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD practice guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.205_bib6","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"21","key":"10.1016\/j.eprac.2025.09.205_bib7","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2025.09.205_bib8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2025.09.205_bib9","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1007\/s10620-021-07089-w","article-title":"Incidence of complications from percutaneous biopsy in chronic liver disease: A systematic review and meta-analysis","volume":"67","author":"Thomaides-Brears","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.eprac.2025.09.205_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/HMER.S278076","article-title":"The need for alternatives to liver biopsies: Non-invasive analytics and diagnostics","volume":"13","author":"Neuberger","year":"2021","journal-title":"HMER"},{"key":"10.1016\/j.eprac.2025.09.205_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241276334","article-title":"Modernizing metabolic dysfunction-associated steatotic liver disease diagnostics: the progressive shift from liver biopsy to noninvasive techniques","volume":"17","author":"Hudson","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.205_bib12","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1097\/HEP.0000000000000262","article-title":"Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis","volume":"77","author":"Sangha","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.205_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43856-025-00796-9","article-title":"Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial","volume":"5","author":"Shumbayawonda","year":"2025","journal-title":"Commun Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.205_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16119","article-title":"Pharmaco-economic assessment of screening strategies for high-risk MASLD in primary care","volume":"45","author":"Younossi","year":"2025","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.205_bib15","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"11","key":"10.1016\/j.eprac.2025.09.205_bib16","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.205_bib17","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"M\u00f3zes","year":"2022","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.eprac.2025.09.205_bib18","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2337\/dc22-0556","article-title":"Noninvasive fibrosis screening in fatty liver disease among vulnerable populations: Impact of diabetes and obesity on FIB-4 score accuracy","volume":"45","author":"Kim","year":"2022","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2025.09.205_bib19","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.dld.2025.05.023","article-title":"Multiparametric magnetic resonance imaging may improve detection of patients with at-risk MASH: Real world experience in hepatology clinics","volume":"57","author":"Phipps","year":"2025","journal-title":"Dig Liver Dis"},{"issue":"7","key":"10.1016\/j.eprac.2025.09.205_bib20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3748\/wjg.v27.i7.609","article-title":"Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort","volume":"27","author":"Imajo","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"11","key":"10.1016\/j.eprac.2025.09.205_bib21","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.cgh.2021.09.041","article-title":"Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: A multicenter pooled data and meta-analysis","volume":"20","author":"Andersson","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.205_bib22","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jhep.2024.08.031","article-title":"Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH","volume":"82","author":"Alkhouri","year":"2025","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.eprac.2025.09.205_bib23","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/liv.14625","article-title":"Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease","volume":"40","author":"Jayaswal","year":"2020","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.205_bib24","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jhep.2023.05.046","article-title":"Liver disease is a significant risk factor for cardiovascular outcomes \u2013 A UK Biobank study","volume":"79","author":"Roca-Fernandez","year":"2023","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.eprac.2025.09.205_bib25","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1038\/s41591-025-03654-2","article-title":"Cardiac and liver impairment on multi-organ MRI and risk of major adverse cardiovascular and liver events","volume":"31","author":"Jackson","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.205_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249491","article-title":"Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort","volume":"16","author":"Beyer","year":"2021","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.eprac.2025.09.205_bib27","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.eprac.2025.09.205_bib28","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.eprac.2025.09.205_bib29","author":"Matsubayashi"},{"key":"10.1016\/j.eprac.2025.09.205_bib30","series-title":"Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment","year":"2018"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.205_bib32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"New Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2025.09.205_bib33","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.eprac.2025.09.205_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03722-7","article-title":"TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial","author":"Noureddin","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.205_bib35","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.31121","article-title":"Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis","volume":"72","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.eprac.2025.09.205_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.575843","article-title":"Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis","volume":"11","author":"Dennis","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eprac.2025.09.205_bib37","article-title":"Change in cT1 following interventions in MASLD: A systematic review and meta-analysis","author":"Andersson","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.eprac.2025.09.205_bib38","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert panel recommendations: Practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis","volume":"22","author":"Noureddin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.205_bib39","doi-asserted-by":"crossref","first-page":"S671","DOI":"10.1016\/S0168-8278(17)31811-1","article-title":"Longitudinal changes in liver stiffness by magnetic resonance elastography (MRE), liver fibrosis, and serum markers of fibrosis in a multi-center clinical trial in nonalcoholic steatohepatitis (NASH)","volume":"66","author":"Loomba","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.eprac.2025.09.205_bib40","series-title":"BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]","year":"2016"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.205_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/0962280214537392","article-title":"Statistical issues in the comparison of quantitative imaging biomarker algorithms using pulmonary nodule volume as an example","volume":"24","author":"Obuchowski","year":"2015","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.205_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0962280214537344","article-title":"Quantitative imaging biomarkers: A review of statistical methods for technical performance assessment","volume":"24","author":"Raunig","year":"2015","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.205_bib43","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12874-020-01179-5","article-title":"COSMIN Risk of Bias tool to assess the quality of studies on reliability or measurement error of outcome measurement instruments: a Delphi study","volume":"20","author":"Mokkink","year":"2020","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.205_bib44","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16127","article-title":"Accuracy of non-invasive imaging techniques for the diagnosis of MASH in patients with MASLD: A systematic review","volume":"45","author":"Cathcart","year":"2025","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.eprac.2025.09.205_bib45","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","article-title":"Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study","volume":"8","author":"Vali","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.eprac.2025.09.205_bib46","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.eprac.2025.09.205_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203054","article-title":"Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial","volume":"13","author":"Harrison","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.205_bib73","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/jmri.29610","article-title":"Quantitative MRI for monitoring metabolic dysfunction-associated steatotic liver disease: A test-retest repeatability study","volume":"61","author":"Beyer","year":"2025","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.205_bib68","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.231092","article-title":"Repeatability of MRI biomarkers in nonalcoholic fatty liver disease: The NIMBLE consortium","volume":"309","author":"Fowler","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.eprac.2025.09.205_bib74","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jmri.26575","article-title":"Accuracy and precision of proton density fat fraction measurement across field strengths and scan intervals: A phantom and human study","volume":"50","author":"Kim","year":"2019","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.eprac.2025.09.205_bib75","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00261-019-02312-9","article-title":"Reproducibility of hepatic MR elastography across field strengths, pulse sequences, scan intervals, and readers","volume":"45","author":"Kim","year":"2020","journal-title":"Abdom Radiol"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.205_bib69","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233094","article-title":"Reproducibility and repeatability of US shear-wave and transient elastography in nonalcoholic fatty liver disease","volume":"312","author":"Pierce","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.eprac.2025.09.205_bib78","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.mri.2021.10.016","article-title":"Free-breathing 3D stack-of-radial MRI quantification of liver fat and R2\u2217 in adults with fatty liver disease","volume":"85","author":"Armstrong","year":"2022","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.eprac.2025.09.205_bib79","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s00261-018-1745-3","article-title":"Inter-reader agreement of magnetic resonance imaging proton density fat fraction and its longitudinal change in a clinical trial of adults with nonalcoholic steatohepatitis","volume":"44","author":"Hooker","year":"2019","journal-title":"Abdom Radiol"},{"issue":"2","key":"10.1016\/j.eprac.2025.09.205_bib80","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1148\/radiol.2017160606","article-title":"Quantifying abdominal adipose tissue and thigh muscle volume and hepatic proton density fat fraction: Repeatability and accuracy of an MR imaging-based, semiautomated analysis method","volume":"283","author":"Middleton","year":"2017","journal-title":"Radiology"},{"issue":"8","key":"10.1016\/j.eprac.2025.09.205_bib81","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1007\/s00261-015-0542-5","article-title":"Intra- and inter-examination repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and complex-based MRI for estimation of hepatic proton density fat fraction in overweight and obese children and adults","volume":"40","author":"Tyagi","year":"2015","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.eprac.2025.09.205_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2024.111709","article-title":"Comparative analysis of hepatic fat quantification across 5 T, 3 T and 1.5 T: A study on consistency and feasibility","volume":"180","author":"Liu","year":"2024","journal-title":"Eur J Radiol"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.205_bib83","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1007\/s00330-021-08381-z","article-title":"MR elastography in nonalcoholic fatty liver disease: inter-center and inter-analysis-method measurement reproducibility and accuracy at 3T","volume":"32","author":"Tang","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eprac.2025.09.205_bib84","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jgh.14782","article-title":"Comparing point shear wave elastography (ElastPQ) and transient elastography for diagnosis of fibrosis stage in non-alcoholic fatty liver disease","volume":"35","author":"Leong","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.205_bib85","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/MPG.0000000000002991","article-title":"Performance characteristics, intra- and inter-operator agreement of transient elastography in pediatric nonalcoholic fatty liver disease","volume":"72","author":"Mandelia","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.eprac.2025.09.205_bib77","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1148\/radiol.2017162931","article-title":"MR spectroscopy-derived proton density fat fraction is superior to controlled attenuation parameter for detecting and grading hepatic steatosis","volume":"286","author":"Runge","year":"2018","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.205_bib86","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/jum.15751","article-title":"Reliability of performing multiparametric ultrasound in adult livers","volume":"41","author":"Gao","year":"2022","journal-title":"J Ultrasound Med"},{"issue":"7","key":"10.1016\/j.eprac.2025.09.205_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219854","article-title":"Intraclass correlation \u2013 A discussion and demonstration of basic features","volume":"14","author":"Liljequist","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.eprac.2025.09.205_bib48","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/hep.32315","article-title":"Placebo effect on progression and regression in NASH: Evidence from a meta-analysis","volume":"75","author":"Ng","year":"2022","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.205_bib49","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","article-title":"Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: Systematic review and meta-analysis","volume":"17","author":"Han","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eprac.2025.09.205_bib50","article-title":"Change in cT1 following interventions in MASLD: A systematic review and meta-analysis","author":"Andersson","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.205_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214921","article-title":"Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver","volume":"14","author":"Bachtiar","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.205_bib53","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.205_bib54","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00261-018-1701-2","article-title":"Reference range of liver corrected T1 values in a population at low risk for fatty liver disease\u2014a UK Biobank sub-study, with an appendix of interesting cases","volume":"44","author":"Mojtahed","year":"2019","journal-title":"Abdom Radiol"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.205_bib55","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/liv.15555","article-title":"The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis","volume":"43","author":"Kugelmas","year":"2023","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.eprac.2025.09.205_bib56","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.205_bib57","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.205_bib58","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1080\/13696998.2025.2550113","article-title":"Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States","volume":"28","author":"Hancock","year":"2025","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.eprac.2025.09.205_bib59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.15403\/jgld.2014.1121.252.lsf","article-title":"Liver stiffness evaluation by transient elastography in type 2 diabetes mellitus patients with ultrasound-proven steatosis","volume":"25","author":"Sporea","year":"2016","journal-title":"JGLD"},{"issue":"11","key":"10.1016\/j.eprac.2025.09.205_bib60","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1136\/gutjnl-2018-317334","article-title":"Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease","volume":"68","author":"Wong","year":"2019","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.205_bib61","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/ajg.2016.49","article-title":"The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease","volume":"111","author":"Tapper","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.eprac.2025.09.205_bib62","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/liv.13284","article-title":"Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity","volume":"37","author":"Pavlides","year":"2017","journal-title":"Liver Int"},{"issue":"11","key":"10.1016\/j.eprac.2025.09.205_bib63","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/diseases12110288","article-title":"Significant within-individual variability in VCTE liver stiffness measurements at two intercostal spaces in subjects with MASLD: Implications for evaluating improvement in liver fibrosis after weight-loss or liver-directed therapy","volume":"12","author":"Woodard","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.eprac.2025.09.205_bib64","article-title":"FibroScan discordance with liver biopsy significantly overestimates advanced fibrosis and cirrhosis in MASLD subjects with class 3 obesity: implications for resmetirom eligibility","author":"Velji-Ibrahim","year":"2025","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.eprac.2025.09.205_bib65","series-title":"Military construction, veterans affairs, and related agencies appropriation bill, 2026","author":"Boozman","year":"2025"},{"key":"10.1016\/j.eprac.2025.09.205_bib66","doi-asserted-by":"crossref","DOI":"10.1007\/s00330-025-11533-0","article-title":"Concordance of vibration-controlled transient elastography and magnetic resonance elastography for fibrosis staging in patients with metabolic dysfunction-associated steatotic liver disease","author":"Mathur","year":"2025","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.205_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25843-6","article-title":"Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD","volume":"12","author":"Nogami","year":"2022","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.eprac.2025.09.205_bib70","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70280","article-title":"Real-World assessment of liver corrected T1 and magnetic resonance elastography in predicting liver disease progression","volume":"45","author":"Corey","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.eprac.2025.09.205_bib71","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001509","article-title":"Non-invasive tests: Establishing efficacy for metabolic dysfunction\u2013associated steatohepatitis beyond the biopsy\u2014Current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration","author":"Anania","year":"2025","journal-title":"Hepatology"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25012303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25012303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T15:44:59Z","timestamp":1770738299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25012303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1530891X25012303"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.09.205","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reliable Monitoring of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Using Imaging: A Systematic Literature Review and Meta-Analysis on Measurement Repeatability","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.09.205","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}